DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20222140
Published: 2022-08-24

COVID-19 impact on the prevalence of PIMS in elderly patients according to STOPP/ START criteria: a record base study

Ankit Bhardwaj, Shoma Mukherjee

Abstract


Background: Polypharmacy, contribute to an increased risk of adverse drug reaction morbidity, and mortality, and increases the length of hospital stay, hospital revisits and readmissions. We aimed to evaluate the prevalence and trends of polypharmacy and potentially inappropriate medications in elderly patients with version 2. STOPP/START criteria, and assess the severity of adverse drug events in patients with PIMs.

Methods: This is a retrospective, record-based study of over-the-counter, and potentially inappropriate medications in the prescriptions of patients (>60 years). PIMs have been identified and further investigated to determine any adverse effects. If harm occurred, the severity of an adverse effect was rated using a modified Hartwig and Siegel scale. The causality of the events was assessed by using Naranjo's scale.

Results: Out of 583 patients polypharmacy and excessive polypharmacy were found in 36.0%, and 42.8% of pre-admission medications. The most common over-the-counter (OTC) drugs were hydrocortisone (39.86%), ranitidine (21.62%), bisacodyl (14.86%), and diphenhydramine (12.84%). A statistically significant positive correlation was seen between age and the number of drugs prescribed (r2=0.16), while a non-significant positive correlation was found between sex, length of stay (LOS), and the number of drugs prescribed (r2 =0.0002, r2 =0.001). Common PIMs related incidence reported include Insulin (regular) 31.25% (N=20), Trihexyphenidyl (THP) 18.75%, zolpidem 12.5%, acetylsalicylic acid 9.3%, pantoprazole 52 7.81%, furosemide 7.8%, hydrocortisone 6.25%, and glimepiride 6.25%. Total of 130 ADRs 50% were mild, 28.4% were moderate, and 21.5% were severe. Out of 130 incidents, 64.6% were preventable, 22.3% were probably preventable, and 13.0% were not preventable. A total of 50.0% recovered completely from the ADRs, 33.0% had been recovering, 12.3% recovered with a squeal, 2.3% could not recover and 2.3% had been fatal.

Conclusions: The study shows high uses of OTC and PIMs and PGx in elderly patients; which encourage intent need to develop awareness and action plans.


Keywords


STOPP/ START criteria, Potentially inappropriate medicines, Polypharmacy, Geriatrics medicines, Over-the-counter drugs

Full Text:

PDF

References


Coronavirus disease 2019 (COVID-19) Situation Report. Available at: https://www.who.int/docs/ default-source/coronaviruse/situation-reports/20200 222- sitrep-33-363. Accessed on 20 October 2022.

Life expectancy. Available at: https://niti.gov.in/ content/life-expectancy. Accessed on 28/12/2020. Accessed on 20 October 2022.

Mishra V. India’s projected aged population (65+), projected life expectancy at birth and insecurities faced by aged population. Ageing Int. 2020;45:72-84.

Hohl CM, Dankoff J, Colacone A. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6): 666-71.

Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. Clin Pharmacokinet. 1988;15(5):287-94.

Rowe JW, Andres R, Tobin JD. The effect of age on creatinine clearance in men: cross-sectional and longitudinal study. J Gerontol. 1976;31(2):155-63.

Suehs BT. Effect of potentially inappropriate use of antimuscarinic medications on healthcare use and cost in individuals with overactive bladder. J Am Geriatr Soc. 2016;64(4):779-87.

Page RL, II SA, Bryant LL, Ruscin JM. Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. 2010;5:75-87.

Gallagher P, Ryan C, Byrne S, et al. Screening tool of older person’s prescriptions and screening tool to alert doctors to right treatment. Consensus validation. Int J Clin Pharmacol Ther 2008;46:72-83.

Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021;11:595219.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.

Caudle K, Klein T, Hoffman J, Muller D, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium guideline development process. Curr Drug Metab. 2014;15:209-17.

Swen JJ, Nijenhuis M, De Boer A, Grandia L, Maitland-Van Der Z, Mulder AH, et al. Pharmacogenetics: from bench to byte an update of guidelines. Clin Pharmacol Ther. 2011;89:662-73.

Gallagher P, Lang PO, Cherubini A, Topinková E, Cruz-Jentoft A, Montero Errasquín B, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011; 67(11):1175-88.

El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447-60.

Ramachandran P, Perisetti A, Gajendran M, et al. Pre hospitalization proton pump inhibitor (PPI) use and clinical outcomes in COVID-19. Medrixv. 2020;34: 23-9.

Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69:543-52.

Chirn-Bin C. Potentially inappropriate medications in geriatric outpatients with polypharmacy: application of six sets of published explicit criteria. Br J Clin Pharmacol. 2011;72(3):482-9.

Saka SA, Nlooto M, Oosthuizen F. American Geriatrics Society-Beers Criteria and adverse drug reactions: a comparative cross-sectional study of Nigerian and South African older inpatients. Clin Interv Aging. 2018 Nov 19;13:2375-2387.

Kuba K, Imai Y, Rao S. A crucial role of angiotensin-converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-9.

Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011; 89:845-54.

Dollar O, Boland B, Loiseau C. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. Drugs Aging 2014;31:291-8

Curtin D, Dukelow T, James K, et al. Deprescribing in multi-morbid older people with polypharmacy: the agreement between STOPPFrail explicit criteria and gold standard deprescribing using 100 standardized clinical cases. Eur J Clin Pharmacol. 2019;75:427-32.

O’Mahony D, O’Sullivan D, Byrne S. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213-8.

Frankenthal D, Lerman Y, Kalendaryev E. Intervention with the screening tool of older persons potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria in elderly residents of a chronic geriatric facility: a randomized clinical trial. J Am Geriatr Soc. 2014;62:1658-65.

Thomas RE. Assessing medication problems in those ⩾65 using the STOPP and START criteria. Curr Aging Sci. 2016;9:150-8.

Schott G, Martinez YV, Ediriweera de Silva RE, Renom-Guiteras A, Vögele A, Reeves D, et al. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing. BMC Geriatr. 2017;17(1):226.

Storms H, Marquet K, Aertgeerts B, et al. Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: a systematic review. Eur J Gen Pract. 2017;23:69-77.

Thomas RE. Assessing medication problems in those ⩾ 65 using the STOPP and START criteria. Curr Aging Sci. 2016;9:150-8.

Any PMS, Strauven GC, Foulon V. Potentially inappropriate prescribing in Belgian nursing homes: prevalence and associated factors. J Am Med Dir Assoc. 2018;19: 884-90.

Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015;19(3):441-5.

Health library. Available at: https://www.mountsinai. org/hea. Accessed on 20 October 2021.

Sediq R, van der Schans J, Dotinga A, Alinghi RA, Wilffert B, Bos JH, et al. Concordance assessment of self-reported medication use in the Netherlands three-generation lifelines cohort study with the pharmacy database iaDB.nl. Pharm lines initiative. Clin Epidemiol. 2018;10:981-9.